Trials / Withdrawn
WithdrawnNCT05809583
Define Predictors of Response to Ozanimod in UC Discovering Biomarkers in the Management of Ulcerative Colitis
Applying Precision Medicine to Define Predictors of Response to Ozanimod and Discovering Biomarkers in the Management of Ulcerative Colitis Using 7,000 Protein SOMAscan
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Beth Israel Deaconess Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A diagnostic tool that identifies biomarkers that predict response prior to and during induction of ozanimod will have a major impact on improving outcomes in UC patients. Using SOMAscan from SomaLogic (Boulder, CO), our study aims to discover serum protein biomarkers in UC patients that predict response to ozanimod and to gain insight into the pathophysiological mechanisms underlying ozanimod response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ozanimod | Patients with established diagnosis of UC starting ozanimod therapy as part of their clinical care |
Timeline
- Start date
- 2023-04-12
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2023-04-12
- Last updated
- 2025-06-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05809583. Inclusion in this directory is not an endorsement.